A leading private healthcare group on Monday said it will provide COVID-19 jabs for free to children with "specified co-morbidities", even as the Centre is yet to announce its approval to it.
Apollo Hospitals, in a statement, said, however, it is an "indicative list" and the "final list of co-morbidities eligible for free vaccination would be as per the list published by the government".
Zydus Cadila's Covid vaccine ZyCoV-D has already received Emergency Use Authorisation from the Drugs Controller General of India (DCGI) in the country and will be administered to those aged 12 years and above. It is yet to be introduced in the nationwide Covid vaccination programme.
As for the emergency use approval for Bharat Biotech's Covaxin in the 2-18 years age group by the DCGI, it is under expert evaluation, official sources had earlier said.
On October 12, the Subject Expert Committee (SEC) on COVID-19 of the central drug authority had recommended granting Emergency Use Authorisation to Covaxin for children and adolescents in the 2-18 years age group with certain conditions.
Apollo Hospitals sources on Monday claimed that the list of co-morbidities announced by the group on Monday was prepared "after consulting with the government".
"It is anticipated that approval will soon be granted for vaccinating children with specified co-morbidities and immediately post-approval, and details of the age-group permitted for vaccination, the free vaccination initiative would be launched by Apollo Hospitals across its units," the statement said.
"The list is expected to include children with haematological, neurological, cardiac, liver, gastrointestinal, rheumatic, cancer, respiratory, genitourinary and developmental disorders," it said.
Dr Prathap C Reddy, Chairman, Apollo Hospitals Group, said, "Adults have been the focus of vaccination till now as by and large, children have been spared from severe Covid infection. However, this is not the case in children with co-morbidities. These children continue to be at high risk of developing a severe infection. In addition, children with comorbidities have also seen a significant psychosocial impact as the lockdown resulted in their missing out on the personalised attention and specialised treatment and care that they require."
The government's approval of vaccination for children with co-morbidities, when it comes through, will be a "welcome step in the right direction", he was quoted as saying in the statement.
"Realising the criticality of this vaccination, we will be extending the Covid vaccines completely free of cost to children with co-morbidities and giving them the necessary 'kavach' (shield) against Covid," Reddy said.
Both vaccines would be available at Apollo Hospitals' vaccination centres across the country once all approvals by the government are in place and the vaccines are made available, the statement said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)